Renal cell carcinoma · 7 regimens
Cost vs Efficacy · 4 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Lenvatinib monotherapy Variant #01 | — | R 74 494 | 28d | ~7.4 mo | — | ~9 | ~R 670 444 PFS proxy · indirect | 1 |
Bevacizumab monotherapy Variant #08 | — | R 57 246 | 21d | ~8.5 mo | — | ~13 | ~R 744 203 PFS proxy · indirect | 1 |
Everolimus and Lenvatinib Variant #01 | — | R 48 788 | 21d | ~14.7 mo | — | ~22 | ~R 1 073 328 PFS proxy · indirect | 4 |
Pazopanib monotherapy Variant #01 | — | R 22 754 | 28d | ~9.2 mo | ~22.9 mo | ~11 | ~R 250 289 PFS proxy · indirect | 4 |
Placebo Partial | — | — | — | — | — | — | — | 1 |
Cyclophosphamide and Fludarabine (FluCy), then allo HSCT Partial | — | — | — | — | — | — | — | — |
Nivolumab monotherapy Variant #01 Partial | — | — | 14d | — | ~69.5 mo | — | — | 3 |
7 of 7 regimens shown